Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646305 | 0.87 | NAMPT (0.49) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6649808 | 0.87 | THRB (0.43) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6645501 | 0.87 | LMNA (0.47) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6646693 | 0.87 | F2 (0.45) | LMNAPOLBHIF1ATHRBNAMPT | |
| SCHEMBL6643623 | 0.87 | SMN1; SMN2 (0.44) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6644882 | 0.85 | THRB (0.46) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6649993 | 0.82 | LMNA (0.43) | LMNAPOLBMAPTHIF1ATHRB | |
| SCHEMBL6643607 | 0.82 | FLT1 (0.43) | LMNATHRBEGLN1JAK2JAK1 | |
| SCHEMBL6646034 | 0.79 | APOB (0.48) | LMNAPOLBMAPTNAMPT | |
| SCHEMBL6644249 | 0.78 | SORT1 (0.47) | LMNAMAPTEGLN1KDRSORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | LMNA 1410/4885POLB 1209/4885MAPT 4101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.